AXSM — Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 712
- Website: https://www.axsome.com
Latest SEC filings for AXSM
- 10-Q — 2026-08-10
- 8-K — 2026-08-10
- 8-K — 2026-07-15
- 8-K — 2026-06-09
- 8-K — 2026-06-09
- 8-K — 2026-06-03
- 10-Q — 2026-05-04
- 8-K — 2026-05-04
- 8-K — 2026-04-30
- ARS — 2026-04-24
Latest AXSM news
- — 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) (The Motley Fool)
- — Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight (GlobeNewswire Inc.)
- — Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? (Zacks Investment Research)
- — Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight (GlobeNewswire Inc.)
- — 2 Under-the-Radar Stocks to Buy and Hold (The Motley Fool)
- — Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? (Zacks Investment Research)
- — Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? (fool.com)
- — 4 CNS Drug Stocks Worth Watching This World Mental Health Day (Zacks Investment Research)
- — 4 CNS Drug Stocks Worth Watching This World Mental Health Day
- — Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Educational tool only — not investment advice.